Table 1 Clinical characteristics of patients with pT3 UTUC.
From: Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma
No Adjuvant Radiotherapy (n = 158) | Adjuvant Radiotherapy (n = 40) | P value | |
|---|---|---|---|
Gender, n (%) | 1.000 | ||
Female | 82 (51.9) | 21 (52.5) | |
Male | 76 (48.1) | 19 (47.5) | |
Age, yrs, median (range) | 70.5 (23.6–91.6) | 65.2 (39.5–82.9) | 0.023 |
Less than 68.6, n (%) | 75 (47.5) | 24 (60.0) | 0.215 |
68.6 or greater, n (%) | 83 (52.5) | 16 (40.0) | |
Current smoking status, n (%) | 0.119 | ||
No | 139 (88.0) | 31 (77.5) | |
Yes | 17 (10.7) | 9 (22.5) | |
Unknown | 2 (1.3) | 0 (0) | |
ASA score, n (%) | 0.931 | ||
1 | 3 (1.9) | 1 (2.5) | |
2 | 70 (44.3) | 19 (47.5) | |
3 | 84 (53.2) | 20 (50.0) | |
4 | 1 (0.6) | 0 (0) | |
Recurrent bladder tumor, n (%) | 41 (25.9) | 8 (20.0) | 0.540 |
Recurrent contralateral UTUC, n (%) | 10 (6.3) | 2 (5.0) | 1.000 |
eGFR (mL/min/1.73 m2), median (range) | 43.1 (0–86.5) | 44.9 (0–77.4) | 0.265 |
Less than 60, n (%) | 132 (83.5) | 33 (82.5) | 0.817 |
60 or greater, n (%) | 26 (16.5) | 7 (17.5) | |
Tumor Grade, n (%) | 0.125 | ||
Low | 11 (7.0) | 0 (0) | |
High | 147 (93.0) | 40 (100) | |
Lymphovascular invasion, n (%) | 31 (19.6) | 9 (22.5) | 0.664 |
Carcinoma in situ, n (%) | 20 (12.7) | 6 (15.0) | 0.793 |
Positive surgical margin, n (%) | 5 (3.2) | 4 (10.0) | 0.084 |
